Physician
Ariga, Reshma
Ariga, Reshma was paid $791K by Medicaid between Jan 2018 and Nov 2024, across 71 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.
33Billing provider infoARIGA, RESHMA
MUNSTER, IN 46321
MUNSTER, IN 46321
33aNPI1558354456assigned 08/25/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$791K
24GClaims126,546
24DCodes billed71
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Indiana
Rank by total paid#8 of 38
Median peer was paid$72K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,630 | $65K | |
| 2019 | 18,280 | $91K | |
| 2020 | 35,234 | $211K | |
| 2021 | 32,283 | $222K | |
| 2022 | 21,346 | $162K | |
| 2023 | 4,806 | $30K | |
| 2024incomplete | 2,967 | $11K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 15% | 3,020 | 2,698 | $119K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 14% | 3,193 | 2,988 | $113K |
| 80053 | Comprehensive metabolic panel | 10% | 15,757 | 11,228 | $79K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.4% | 20,451 | 12,102 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.0% | 1,802 | 1,585 | $39K |
| 84484 | 4.8% | 7,412 | 5,232 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.8% | 7,260 | 3,148 | $30K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.3% | 1,168 | 1,066 | $26K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.3% | 1,163 | 1,061 | $26K |
| 83735 | 3.2% | 7,565 | 3,915 | $26K | |
| 87040 | 2.6% | 1,633 | 1,191 | $20K | |
| 83880 | 2.2% | 1,821 | 1,377 | $17K |
59 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.0% | 912 | $16K |
| 83690 | 1.9% | 4,442 | $15K | |
| 83605 | 1.7% | 2,592 | $14K | |
| 81001 | 1.4% | 7,133 | $11K | |
| 81025 | 1.4% | 5,479 | $11K | |
| 82805 | 1.3% | 898 | $10K | |
| 85730 | 1.2% | 2,831 | $10K | |
| 85027 | 1.2% | 3,295 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 1,809 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 513 | $9K |
| 87641 | 1.0% | 372 | $8K | |
| 85610 | <1% | 3,917 | $7K | |
| 87430 | <1% | 845 | $7K | |
| 87186 | <1% | 889 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 239 | $5K |
| 85379 | <1% | 1,377 | $5K | |
| 86901 | <1% | 1,497 | $3K | |
| 84702 | <1% | 680 | $3K | |
| 84105 | <1% | 2,019 | $3K | |
| 86900 | <1% | 1,493 | $3K | |
| 86850 | <1% | 851 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 804 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 286 | $2K |
| 82728 | <1% | 589 | $2K | |
| 81003 | <1% | 1,858 | $2K | |
| 87081 | <1% | 650 | $2K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 23 | $2K |
| 82248 | <1% | 1,251 | $2K | |
| 87210 | <1% | 601 | $1K | |
| 86140 | <1% | 581 | $1K | |
| 80061 | Lipid panel | <1% | 432 | $1K |
| 86769 | <1% | 68 | $1K | |
| 82607 | <1% | 193 | $1K | |
| 87449 | <1% | 132 | $1K | |
| 85651 | <1% | 429 | $954.50 | |
| 84145 | <1% | 361 | $930.81 | |
| 87420 | <1% | 105 | $845.01 | |
| 80069 | <1% | 188 | $724.20 | |
| 87631 | <1% | 13 | $687.70 | |
| 82140 | <1% | 140 | $580.99 | |
| 84703 | <1% | 130 | $464.41 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 22 | $412.46 |
| 87486 | <1% | 23 | $412.20 | |
| 87581 | <1% | 23 | $412.20 | |
| 84100 | <1% | 154 | $356.22 | |
| 87340 | <1% | 51 | $337.50 | |
| 85384 | <1% | 115 | $312.52 | |
| 82550 | <1% | 124 | $297.05 | |
| 83615 | <1% | 164 | $296.04 | |
| 82746 | <1% | 62 | $292.23 | |
| 87205 | <1% | 151 | $287.00 | |
| 83550 | <1% | 62 | $248.24 | |
| 83540 | <1% | 64 | $191.40 | |
| 80076 | <1% | 63 | $186.47 | |
| 83520 | <1% | 26 | $145.82 | |
| 87077 | <1% | 199 | $139.52 | |
| 87070 | <1% | 33 | $114.70 | |
| 86920 | <1% | 36 | $96.35 | |
| 86704 | <1% | 12 | $86.35 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.